NCT02519855View on ClinicalTrials.gov

Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)

PHASE3CompletedINTERVENTIONAL
Enrollment

882

Participants

Timeline

Start Date

September 11, 2015

Primary Completion Date

January 26, 2016

Study Completion Date

January 26, 2016

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

ZOSTAVAX™

A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (concomitant) or at Week 4 (nonconcomitant)

BIOLOGICAL

Placebo to ZOSTAVAX™

A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (nonconcomitant) or at Week 4 (concomitant)

BIOLOGICAL

Influenza Vaccine

A single open-label administration of 0.5 mL intramuscular injection on Day 1

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02519855 - Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062) | Biotech Hunter | Biotech Hunter